Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
130,702,820
-
Total 13F shares
-
23,438,674
-
Share change
-
+352,332
-
Total reported value
-
$146,961,556
-
Put/Call ratio
-
182%
-
Price per share
-
$6.27
-
Number of holders
-
59
-
Value change
-
+$2,094,667
-
Number of buys
-
30
-
Number of sells
-
21
Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q3 2017
As of 30 Sep 2017,
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,438,674 shares.
The largest 10 holders included
FMR LLC, NEA Management Company, LLC, ORBIMED ADVISORS LLC, Polar Capital LLP, FRANKLIN RESOURCES INC, Vivo Capital, LLC, GOLDMAN SACHS GROUP INC, Alyeska Investment Group, L.P., MORGAN STANLEY, and Balyasny Asset Management LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.